ArticleScientific reports2025
Circ_0003266 suppresses bladder cancer progression by modulating the miR-503-5p/SMAD7/TGF-β signaling axis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The YTHDC1/HECW1/SMAD7 axis drives cisplatin resistance in bladder cancer.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Circular RNAs (circRNAs) have emerged as critical regulators in cancer progression. This study aimed to investigate the role of circ_0003266 in bladder cancer (BCa) and elucidate its underlying molecular mechanisms. The expression levels of circ_0003266, miR-503-5p, and SMAD7 in BCa tissues and cell lines were determined using bioinformatics analysis, clinical data, and quantitative real-time PCR (qPCR). Cellular phenotypes were evaluated through proliferation, migration, and apoptosis assays. RNA pull-down and luciferase reporter assays were conducted to validate the molecular interactions among circ_0003266, miR-503-5p, and SMAD7. The involvement of the TGF-β signaling pathway was assessed by Western blotting and co-immunoprecipitation (Co-IP) analysis. Circ_0003266 expression was significantly downregulated in BCa tissues and cell lines, and its low expression was clinically correlated with larger tumor size and advanced disease stage, including poor differentiation and higher TNM classification. Upregulation of circ_0003266 inhibited BCa cell proliferation and migration while promoting apoptosis. Mechanistic analyses revealed that miR-503-5p is a direct target of circ_0003266, and that circ_0003266-mediated regulation of miR-503-5p subsequently modulates SMAD7 expression. SMAD7, a well-established inhibitor of the TGF-β pathway, was shown to mediate the tumor-suppressive effects of circ_0003266. In vivo experiments confirmed that overexpression of circ_0003266 attenuated tumor growth and suppressed TGF-β signaling activity. Our findings demonstrate that circ_0003266 exerts tumor-suppressive functions in BCa by modulating the miR-503-5p/SMAD7/TGF-β axis, highlighting its potential as a novel therapeutic target for bladder cancer intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.